Maverix Medical Closes Acquisition of Cirrus Bio as Foundation for Diagnostics Platform in Lung Cancer

Maverix Medical, a dedicated lung cancer platform established by Ajax Health, KKR, and Hologic, Inc., has announced the acquisition of Cirrus Bio for an undisclosed amount. Cirrus Bio develops and brings to market multiomic solutions for the diagnosis and management of diseases where early detection plays a critical role in clinical outcomes. As part of the acquisition, Maverix also announced the formation of a dedicated diagnostic division called Maverix Dx that will develop, invest in, acquire, and bring to market a suite of diagnostic tools for lung cancer. Cirrus represents the second major new product platform for Maverix. The first—Serpex Medical, announced at closing—has developed and obtained 510k clearance for steerable technologies that can precisely target lung tissue for biopsy or therapy delivery.

Read the full article: Maverix Medical Closes Acquisition of Cirrus Bio as Foundation for Diagnostics Platform in Lung Cancer //

Source: https://www.prnewswire.com/news-releases/maverix-medical-closes-acquisition-of-cirrus-bio-as-foundation-for-diagnostics-platform-in-lung-cancer-302103254.html

Leave a Comment

Your email address will not be published.

Scroll to Top